FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 339:849-851 September 17, 1998 Number 12 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Gleave, M. E. Related Article by Negrier, S.

To the Editor: We have three questions about the article by Gleave et al. (April 30 issue)¹ on cytokine therapy in patients with metastatic renal cancer. First, the incidence of "spontaneous" remissions was higher than that previously reported. Was there any histologic confirmation of metastatic disease in the patients who had responses? Second, are there any data on second-line therapy? It is possible that treatment with interferon alfa or interleukin-2 in a large proportion of patients may have skewed the final survival curves. Finally, survival at two years appears to have been 5 percent in the placebo group, whereas it . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.